dexamfetamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anorexics 841 51-64-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dextroamphetamine
  • S-Amphetamine
  • D-Amphetamine
  • dexadrine
  • dexamfetamine
  • dextroamphetamine sulfate
  • dextroamphetamine saccharate
  • dextroamphetamine adipate
  • dextroamphetamine resin complex
The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
  • Molecular weight: 135.21
  • Formula: C9H13N
  • CLOGP: 1.74
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -1.89
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.40 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 75 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Sept. 9, 1955 FDA UCB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anxiety 79.28 15.41 116 7881 217425 63263600
Coronary artery dissection 69.04 15.41 17 7980 845 63480180
Migraine 66.11 15.41 73 7924 103273 63377752
Pre-existing condition improved 62.05 15.41 27 7970 8217 63472808
Depression 60.57 15.41 97 7900 196395 63284630
Suicidal ideation 48.63 15.41 49 7948 62372 63418653
Feeling abnormal 45.33 15.41 73 7924 148319 63332706
Cataplexy 44.48 15.41 13 7984 1243 63479782
Suspected product quality issue 37.18 15.41 8 7989 217 63480808
Product substitution issue 35.05 15.41 23 7974 15973 63465052
Sleep apnoea syndrome 30.59 15.41 27 7970 29106 63451919
Snoring 29.15 15.41 13 7984 4189 63476836
Somnolence 28.72 15.41 67 7930 178618 63302407
Therapeutic response unexpected 27.26 15.41 21 7976 18738 63462287
Neuroleptic malignant syndrome 25.60 15.41 17 7980 12039 63468986
Memory impairment 23.62 15.41 45 7952 104213 63376812
Weight decreased 23.13 15.41 82 7915 276716 63204309
Disturbance in attention 22.71 15.41 26 7971 38163 63442862
Overdose 20.53 15.41 45 7952 115033 63365992
Colitis ischaemic 20.12 15.41 14 7983 10694 63470331
Product dose omission issue 18.36 15.41 68 7929 234245 63246780
Rhabdomyolysis 18.25 15.41 25 7972 43926 63437099
Serotonin syndrome 17.86 15.41 20 7977 28662 63452363
Contraindicated product administered 17.82 15.41 3 7994 217645 63263380
Hypothermia 17.15 15.41 14 7983 13567 63467458
Muscle rigidity 16.98 15.41 13 7984 11487 63469538
Dermatitis atopic 16.62 15.41 12 7985 9712 63471313
Headache 16.53 15.41 136 7861 633105 62847920
Bipolar disorder 16.36 15.41 11 7986 7949 63473076
Intentional self-injury 16.14 15.41 18 7979 25669 63455356
Intentional overdose 15.56 15.41 31 7966 74121 63406904

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oppositional defiant disorder 112.27 24.37 23 4087 526 34952295
Decreased eye contact 108.69 24.37 22 4088 473 34952348
Aggression 94.16 24.37 58 4052 38906 34913915
Bruxism 90.70 24.37 24 4086 1711 34951110
Product substitution issue 81.39 24.37 34 4076 10061 34942760
Coordination abnormal 79.77 24.37 31 4079 7613 34945208
Crying 76.50 24.37 28 4082 5834 34946987
Homicidal ideation 76.04 24.37 23 4087 2659 34950162
Suicidal ideation 75.08 24.37 51 4059 40337 34912484
Anxiety 65.59 24.37 69 4041 99359 34853462
Choreoathetosis 61.78 24.37 16 4094 1048 34951773
Affect lability 61.00 24.37 21 4089 3662 34949159
Poor quality sleep 57.26 24.37 25 4085 8231 34944590
Trismus 56.43 24.37 18 4092 2477 34950344
Depression 54.64 24.37 62 4048 97036 34855785
Irritability 50.23 24.37 33 4077 24657 34928164
Mood altered 49.05 24.37 23 4087 8929 34943892
Insomnia 46.39 24.37 59 4051 103848 34848973
Psychomotor hyperactivity 44.47 24.37 22 4088 9600 34943221
Speech disorder 44.31 24.37 31 4079 25655 34927166
Posterior reversible encephalopathy syndrome 43.77 24.37 22 4088 9932 34942889
Hyperkinesia 40.99 24.37 13 4097 1755 34951066
Streptococcal infection 40.95 24.37 17 4093 4944 34947877
Depressed mood 37.30 24.37 25 4085 19292 34933529
Dyskinesia 36.22 24.37 26 4084 22387 34930434
Sleep disorder 34.31 24.37 29 4081 31659 34921162
Hypertensive emergency 34.18 24.37 10 4100 1030 34951791
Sleep apnoea syndrome 33.82 24.37 24 4086 20297 34932524
Dystonia 33.64 24.37 19 4091 10826 34941995
Therapeutic response unexpected 32.74 24.37 18 4092 9739 34943082
Extrasystoles 31.21 24.37 13 4097 3810 34949011
Anger 29.44 24.37 18 4092 11866 34940955
Supraventricular extrasystoles 28.88 24.37 12 4098 3496 34949325
Drug ineffective 27.52 24.37 116 3994 456635 34496186
Tic 27.47 24.37 10 4100 2048 34950773
Vision blurred 26.90 24.37 30 4080 45933 34906888
Product complaint 25.83 24.37 13 4097 5877 34946944
Educational problem 25.71 24.37 7 4103 555 34952266
Sexual dysfunction 25.00 24.37 13 4097 6290 34946531

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oppositional defiant disorder 115.96 17.22 23 8782 474 79735109
Decreased eye contact 97.79 17.22 22 8783 843 79734740
Anxiety 92.53 17.22 125 8680 248387 79487196
Product substitution issue 83.50 17.22 42 8763 20214 79715369
Aggression 80.76 17.22 57 8748 50901 79684682
Bruxism 80.27 17.22 26 8779 4000 79731583
Homicidal ideation 75.80 17.22 24 8781 3433 79732150
Coronary artery dissection 71.41 17.22 18 8787 1126 79734457
Suicidal ideation 70.31 17.22 62 8743 76278 79659305
Depression 70.14 17.22 102 8703 216688 79518895
Crying 56.75 17.22 34 8771 23009 79712574
Coordination abnormal 54.56 17.22 30 8775 17282 79718301
Choreoathetosis 52.09 17.22 15 8790 1555 79734028
Affect lability 45.38 17.22 23 8782 11236 79724347
Overdose 44.70 17.22 76 8729 184130 79551453
Feeling abnormal 44.46 17.22 70 8735 159129 79576454
Trismus 43.73 17.22 18 8787 5449 79730134
Poor quality sleep 42.09 17.22 28 8777 22694 79712889
Psychomotor hyperactivity 41.84 17.22 25 8780 16824 79718759
Mood altered 40.51 17.22 25 8780 17822 79717761
Dyskinesia 40.47 17.22 36 8769 44737 79690846
Irritability 39.03 17.22 34 8771 41110 79694473
Intentional overdose 37.36 17.22 52 8753 105908 79629675
Hyperkinesia 36.25 17.22 13 8792 2716 79732867
Speech disorder 34.50 17.22 36 8769 54409 79681174
Intentional self-injury 33.21 17.22 28 8777 32391 79703192
Streptococcal infection 32.59 17.22 17 8788 8813 79726770
Dystonia 31.73 17.22 23 8782 21376 79714207
Sleep disorder 30.13 17.22 42 8763 85635 79649948
Insomnia 29.66 17.22 76 8729 245094 79490489
Posterior reversible encephalopathy syndrome 29.63 17.22 24 8781 26257 79709326
Serotonin syndrome 28.93 17.22 30 8775 44997 79690586
Educational problem 28.27 17.22 7 8798 407 79735176
Tic 27.92 17.22 11 8794 2975 79732608
Depressed mood 27.09 17.22 30 8775 48450 79687133
Cataplexy 26.92 17.22 8 8797 926 79734657
Extrasystoles 26.57 17.22 14 8791 7405 79728178
Hypertensive emergency 25.13 17.22 10 8795 2775 79732808
Supraventricular extrasystoles 24.50 17.22 13 8792 6974 79728609
Therapeutic response unexpected 24.16 17.22 19 8786 19927 79715656
Plagiocephaly 24.01 17.22 4 8801 29 79735554
Abnormal behaviour 22.92 17.22 24 8781 36397 79699186
Nervousness 22.80 17.22 23 8782 33392 79702191
Anger 22.21 17.22 17 8788 17145 79718438
Shoulder operation 21.80 17.22 9 8796 2743 79732840
Neutropenia 21.74 17.22 3 8802 287707 79447876
Cardio-respiratory arrest 21.47 17.22 41 8764 108469 79627114
Pre-existing condition improved 21.36 17.22 11 8794 5552 79730031
Suicide attempt 21.12 17.22 35 8770 82897 79652686
Anaemia 20.30 17.22 12 8793 445003 79290580
Agitation 20.13 17.22 38 8767 99677 79635906
Somnolence 20.07 17.22 65 8740 238916 79496667
Disturbance in attention 19.51 17.22 26 8779 50775 79684808
Neutrophil hypersegmented morphology present 19.51 17.22 3 8802 12 79735571
Colitis ischaemic 19.40 17.22 15 8790 15344 79720239
Product quality issue 18.96 17.22 21 8784 33919 79701664
Psychiatric decompensation 18.66 17.22 9 8796 3954 79731629
Gross motor delay 18.27 17.22 4 8801 135 79735448
Pneumonia 18.22 17.22 28 8777 660218 79075365
Muscle rigidity 17.99 17.22 16 8789 19866 79715717
Fatigue 17.66 17.22 168 8637 929559 78806024

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06BA02 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:35640 adrenergic uptake inhibitors
CHEBI has role CHEBI:37962 adrenergic agents
CHEBI has role CHEBI:48560 dopaminergic agents
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:51039 dopamine reuptake inhibitor
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D015259 Dopamine Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
FDA PE N0000175729 Central Nervous System Stimulation
FDA EPC N0000175739 Central Nervous System Stimulant

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Narcolepsy indication 60380001 DOID:8986
Attention deficit hyperactivity disorder indication 406506008
Gilles de la Tourette's syndrome contraindication 5158005 DOID:11119
Dependent drug abuse contraindication 6525002
Bipolar disorder contraindication 13746004 DOID:3312
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Anorexia nervosa contraindication 56882008 DOID:8689
Aggressive behavior contraindication 61372001
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001
Cardiomyopathy contraindication 85898001 DOID:0050700
Weight loss contraindication 89362005
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Motor tic disorder contraindication 230337001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.89 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
12.5MG;12.5MG;12.5MG;12.5MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG;3.125MG;3.125MG;3.125MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG;6.25MG;6.25MG;6.25MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG;9.375MG;9.375MG;9.375MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
12.5MG;12.5MG;12.5MG;12.5MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG;3.125MG;3.125MG;3.125MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG;6.25MG;6.25MG;6.25MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG;9.375MG;9.375MG;9.375MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
13.5MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL 9456993 Oct. 24, 2033 A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
18MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL 9456993 Oct. 24, 2033 A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
4.5MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL 9456993 Oct. 24, 2033 A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
9MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL 9456993 Oct. 24, 2033 A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
12.5MG;12.5MG;12.5MG;12.5MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL March 13, 2023 PEDIATRIC EXCLUSIVITY
3.125MG;3.125MG;3.125MG;3.125MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL March 13, 2023 PEDIATRIC EXCLUSIVITY
6.25MG;6.25MG;6.25MG;6.25MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL March 13, 2023 PEDIATRIC EXCLUSIVITY
9.375MG;9.375MG;9.375MG;9.375MG MYDAYIS TAKEDA PHARMS USA N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL March 13, 2023 PEDIATRIC EXCLUSIVITY
13.5MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL March 22, 2025 NEW PRODUCT
18MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL March 22, 2025 NEW PRODUCT
4.5MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL March 22, 2025 NEW PRODUCT
9MG/9HR XELSTRYM NOVEN PHARMS INC N215401 March 22, 2022 RX SYSTEM TRANSDERMAL March 22, 2025 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Synaptic vesicular amine transporter Transporter INHIBITOR CHEMBL CHEMBL
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 7 IUPHAR CHEMBL
Sodium-dependent dopamine transporter Transporter RELEASING AGENT Ki 6.68 WOMBAT-PK CHEMBL
Alpha-1A adrenergic receptor GPCR WOMBAT-PK
Cocaine- and amphetamine-regulated transcript protein Transcription factor WOMBAT-PK
Amine oxidase [flavin-containing] A Enzyme Ki 4.84 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 6.87 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 5.24 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.18 PDSP
Sodium-dependent serotonin transporter Transporter EC50 5.75 CHEMBL
Sodium-dependent dopamine transporter Transporter IC50 5.31 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 4.91 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 6 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 7.25 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 8.70 CHEMBL
Serotonin (5-HT) receptor GPCR Kd 5.35 CHEMBL

External reference:

IDSource
4019978 VUID
N0000148062 NUI
D02078 KEGG_DRUG
51-63-8 SECONDARY_CAS_RN
350708-40-6 SECONDARY_CAS_RN
221088 RXNORM
4018004 VANDF
4018005 VANDF
4018835 VANDF
4019978 VANDF
C0011812 UMLSCUI
CHEBI:4469 CHEBI
1WE PDB_CHEM_ID
CHEMBL612 ChEMBL_ID
CHEMBL3544971 ChEMBL_ID
CHEMBL3989844 ChEMBL_ID
DB01576 DRUGBANK_ID
2147 IUPHAR_LIGAND_ID
64770-52-1 SECONDARY_CAS_RN
5826 PUBCHEM_CID
1604 MMSL
40549 MMSL
4563 MMSL
4564 MMSL
d00804 MMSL
001793 NDDF
001795 NDDF
006720 NDDF
387022005 SNOMEDCT_US
387278002 SNOMEDCT_US
45207006 SNOMEDCT_US
50868004 SNOMEDCT_US
D003913 MESH_DESCRIPTOR_UI
CHEMBL1200782 ChEMBL_ID
1430 INN_ID
TZ47U051FI UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1328 CAPSULE, EXTENDED RELEASE 1.25 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1328 CAPSULE, EXTENDED RELEASE 1.25 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1329 CAPSULE, EXTENDED RELEASE 2.50 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1329 CAPSULE, EXTENDED RELEASE 2.50 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1330 CAPSULE, EXTENDED RELEASE 3.75 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1330 CAPSULE, EXTENDED RELEASE 3.75 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1331 CAPSULE, EXTENDED RELEASE 5 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1331 CAPSULE, EXTENDED RELEASE 5 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1332 CAPSULE, EXTENDED RELEASE 6.25 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1332 CAPSULE, EXTENDED RELEASE 6.25 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1333 CAPSULE, EXTENDED RELEASE 7.50 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1333 CAPSULE, EXTENDED RELEASE 7.50 mg ORAL NDA AUTHORIZED GENERIC 36 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1490 CAPSULE 6.25 mg ORAL ANDA 28 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1490 CAPSULE 6.25 mg ORAL ANDA 28 sections